Browse

Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer

DC Field Value Language
dc.contributor.authorPark, So Yeon-
dc.contributor.authorLee, Hee Eun-
dc.contributor.authorLi, Hailun-
dc.contributor.authorShipitsin, Michail-
dc.contributor.authorPolyak, Kornelia-
dc.contributor.authorGelman, Rebecca-
dc.date.accessioned2012-05-31T06:30:00Z-
dc.date.available2012-05-31T06:30:00Z-
dc.date.issued2010-02-01-
dc.identifier.citationCLINICAL CANCER RESEARCH; Vol.16 3; 876-887ko_KR
dc.identifier.issn1078-0432-
dc.identifier.urihttps://hdl.handle.net/10371/76689-
dc.description.abstractPurpose: To evaluate the expression of stem cell-related markers at the cellular level in human breast tumors of different subtypes and histologic stage. Experimental Design: We performed immunohistochemical analyses of 12 proteins [CD44, CD24, ALDH1, vimentin, osteonectin, EPCR, caveolin 1, connexin 43, cytokeratin 18 (CK18), MUC1, claudin 7, and GATA3] selected based on their differential expression in breast cancer cells with more differentiated and stem cell-like characteristics in 47 cases of invasive ductal carcinoma (IDC) only, 135 cases of IDC with ductal carcinoma in situ (DCIS), 35 cases of DCIS with microinvasion, and 58 cases of pure DCIS. We also analyzed 73 IDCs with adjacent DCIS to determine the differences in the expression of markers by histology within individual tumors. CD44+/CD24- and CD24-/CD24+ cells were detected using double immunohistochemistry. Results: CD44 and EPCR expression was different among the four histologic groups and was lower in invasive compared with in situ tumors, especially in luminal A subtype. The expression of vimentin, osteonectin, connexin 43, ALDH1, CK18, GATA3, and MUC1 differed by tumor subtype in some histologic groups. ALDH1-positive cells were more frequent in basal-like and HER2+ than in luminal tumors. CD44+/CD24- cells were detected in 69% of all tumors with 100% of the basal-like and 52% of HER2+ tumors having some of these cells. Conclusions: Our findings suggest that in breast cancer, the frequency of tumor cells positive for stem cell-like and more differentiated cell markers varies according to tumor subtype and histologic stage. Clin Cancer Res; 16(3); 876-87. (C) 2010 AACR.ko_KR
dc.language.isoenko_KR
dc.publisherAMER ASSOC CANCER RESEARCHko_KR
dc.subjectbreast cancerko_KR
dc.subjecttumor progressionko_KR
dc.subjectDCISko_KR
dc.subjectheterogeneityko_KR
dc.titleHeterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancerko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor박소연-
dc.contributor.AlternativeAuthor이희은-
dc.identifier.doi10.1158/1078-0432.CCR-09-1532-
dc.citation.journaltitleCLINICAL CANCER RESEARCH-
dc.description.citedreferenceShackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017-
dc.description.citedreferenceCreighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106-
dc.description.citedreferenceLim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000-
dc.description.citedreferenceRosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837-
dc.description.citedreferenceHennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441-
dc.description.citedreferenceCharafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741-
dc.description.citedreferenceVisvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499-
dc.description.citedreferenceKorkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207-
dc.description.citedreferenceBloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105-
dc.description.citedreferenceXiao Y, 2008, AM J PATHOL, V173, P561, DOI 10.2353/ajpath.2008.071214-
dc.description.citedreferenceRaouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018-
dc.description.citedreferenceMylona E, 2008, HUM PATHOL, V39, P1096, DOI 10.1016/j.humpath.2007.12.003-
dc.description.citedreferenceMani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027-
dc.description.citedreferenceHyun CL, 2008, J CLIN PATHOL, V61, P317, DOI 10.1136/jcp.2007.050336-
dc.description.citedreferenceSarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017-
dc.description.citedreferenceAllred DC, 2008, CLIN CANCER RES, V14, P370, DOI 10.1158/1078-0432.CCR-07-1127-
dc.description.citedreferenceFillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982-
dc.description.citedreferenceHoneth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108-
dc.description.citedreferenceWright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855-
dc.description.citedreferenceCharafe-Jauffret E, 2008, PATHOBIOLOGY, V75, P75, DOI 10.1159/000123845-
dc.description.citedreferenceGinestier C, 2007, CELL STEM CELL, V1, P555-
dc.description.citedreferencePolyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295-
dc.description.citedreferenceCampbell LL, 2007, CELL CYCLE, V6, P2332-
dc.description.citedreferenceShipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013-
dc.description.citedreferenceBeaulieu LM, 2007, EXP CELL RES, V313, P677, DOI 10.1016/j.yexcr.2006.11.019-
dc.description.citedreferenceAsselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530-
dc.description.citedreferenceChaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298-
dc.description.citedreferenceKouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048-
dc.description.citedreferenceCarey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492-
dc.description.citedreferenceSorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127-
dc.description.citedreferenceClarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011-
dc.description.citedreferencePolyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379-
dc.description.citedreferenceSheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610-
dc.description.citedreferenceBaumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619-
dc.description.citedreferenceAbraham BK, 2005, CLIN CANCER RES, V11, P1154-
dc.description.citedreferenceBlanpain C, 2004, CELL, V118, P635-
dc.description.citedreferenceNielsen TO, 2004, CLIN CANCER RES, V10, P5367-
dc.description.citedreferenceThiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006-
dc.description.citedreferenceKristiansen G, 2003, CLIN CANCER RES, V9, P4906-
dc.description.citedreferenceAl-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100-
dc.description.citedreferencePark SY, 2002, HUM PATHOL, V33, P1078, DOI 10.1053/hupa.2002.129422-
dc.description.citedreferenceRamalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530-
dc.description.citedreferenceIvanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823-
dc.description.citedreferenceSorlie T, 2001, P NATL ACAD SCI USA, V98, P10869-
dc.description.citedreferencePerou CM, 2000, NATURE, V406, P747-
dc.description.citedreferenceGraff JR, 2000, J BIOL CHEM, V275, P2727-
dc.description.citedreferenceHEPPNER GH, 1983, CANCER METAST REV, V2, P5-
dc.description.citedreferenceNOWELL PC, 1976, SCIENCE, V194, P23-
dc.description.tc42-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pathology (병리학전공)Journal Papers (저널논문_병리학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse